Shares of Rambus (RMBS) have gained 23.3% over the past four weeks to close the last trading session at $56.35, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $72.25 indicates a potential upside of 28.2%.The mean estimate comprises eight short-term price targets with a standard deviation of $9.97. While the lowest estimate of $55 indicates a 2.4% decline from the current price ...

Shares of CI&T Inc. (CINT) have gained 21.5% over the past four weeks to close the last trading session at $6.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $8.23 indicates a potential upside of 34.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $1.33. While the lowest estimate of $6.50 indicates a 6.6% increase from the current pr ...

HNI (HNI) closed the last trading session at $47.92, gaining 16.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66 indicates a 37.7% upside potential.The average comprises three short-term price targets ranging from a low of $63 to a high of $70, with a standard deviation of $3.61. While the lowest estimate indicates an increase of 31.5% from the current price level, the most o ...

Group 1 - Vertical Aerospace Ltd. (EVTL) shares have increased by 64.9% over the past four weeks, closing at $5.69, with a mean price target of $10.30 indicating a potential upside of 81% [1] - The average price targets range from a low of $2 to a high of $15, with a standard deviation of $5.14, suggesting variability in analyst estimates [2] - Analysts have shown a strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 4.9% over the past month, indicating positive sentiment among analysts [12] - EVTL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide guidance on the direction of price movement [13]

Group 1 - Candel Therapeutics, Inc. (CADL) closed at $5.11, with an 11.8% gain over the past four weeks, and a mean price target of $21 suggests a 311% upside potential [1] - The average price targets range from a low of $15 to a high of $25, with a standard deviation of $4.90, indicating a variability in estimates; the lowest estimate suggests a 193.5% increase, while the highest indicates a 389.2% upside [2] - Analysts show strong agreement on CADL's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for CADL's current year earnings has increased by 17.5%, with one estimate moving higher and no negative revisions [12] - CADL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside in the near term [13]

Group 1 - Immunocore Holdings PLC (IMCR) closed at $29.06, with a 2.3% gain over the past four weeks, and has a mean price target of $62.29, indicating an upside potential of 114.4% [1] - The average of 14 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $23.44, suggesting variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 42.9% over the last 30 days, with seven estimates moving higher and no negative revisions [12] - IMCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [13]

MoonLake Immunotherapeutics (MLTX) closed the last trading session at $36.99, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $76.43 indicates a 106.6% upside potential.The mean estimate comprises 14 short-term price targets with a standard deviation of $13.12. While the lowest estimate of $55 indicates a 48.7% increase from the current price level, the most optimistic ...

QuinStreet (QNST) closed the last trading session at $15.88, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $28.40 indicates a 78.8% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.90. While the lowest estimate of $19 indicates a 19.7% increase from the current price level, the most optimistic analyst expects ...

Group 1 - Pagaya Technologies Ltd. (PGY) closed at $14.96, with a 49.8% gain over the past four weeks, and a mean price target of $22.69 suggests a 51.7% upside potential [1] - The average price targets from analysts range from a low of $13.75 to a high of $36, with a standard deviation of $7.04, indicating variability in estimates [2] - Analysts show strong agreement on PGY's ability to report better earnings, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for PGY's current year earnings has increased by 2.8% over the last 30 days, with no negative revisions [12] - PGY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [13]

Group 1 - Xperi (XPER) has shown a significant price increase of 27.7% over the past four weeks, with a mean price target of $18.25 indicating an upside potential of 118.8% [1] - The average price target ranges from a low of $12 to a high of $30, with a standard deviation of $8.02, suggesting variability in analysts' estimates [2] - The consensus price target is not the sole metric for investment decisions, as analysts' ability to set accurate price targets has been questioned [3] Group 2 - Strong agreement among analysts regarding XPER's earnings prospects, indicated by positive earnings estimate revisions, supports the expectation of stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for XPER's current year earnings has increased by 46.2%, with no negative revisions [12] - XPER holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]